{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["147(4)"],"submitter":["Badrising SK"],"funding":["Bayer HealthCare"],"pubmed_abstract":["The ALSYMPCA study established a 3.6 month Overall Survival (OS) benefit in metastatic Castration Resistant Prostate Cancer (mCRPC) patients treated with Radium-223 dichloride (Ra-223) over placebo. Here we report clinical outcomes of Ra-223 treatment in a nonstudy population. In this prospective registry, patients from 20 Dutch hospitals were included prior to Ra-223 treatment. Clinical parameters collected included previous treatments and Adverse Events. Primary outcome was 6 months Symptomatic Skeletal Event (SSE)-free survival, while secondary outcomes included Progression-Free Survival (PFS) and Overall Survival (OS). Of the 305 patients included, 300 were evaluable. The mean age was 73.6 years, 90% had ≥6 bone metastases and 74.1% were pretreated with Docetaxel, 19.5% with Cabazitaxe"],"journal":["International journal of cancer"],"pagination":["1143-1151"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7383569"],"repository":["biostudies-literature"],"pubmed_title":["A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population."],"pmcid":["PMC7383569"],"pubmed_authors":["Coenen JLLM","Vegt E","Louhanepessy RD","van der Noort V","Oostdijk A","Loosveld OJL","Bergman AM","Hamberg P","Celik F","Haanen JB","Zwart W","Wagenaar N","Zuetenhorst H","Beeker A","Lam MGEH","Badrising SK","ROTOR investigators and the Dutch Uro-Oncology Study group (DUOS15101)"],"additional_accession":[]},"is_claimable":false,"name":"A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.","description":"The ALSYMPCA study established a 3.6 month Overall Survival (OS) benefit in metastatic Castration Resistant Prostate Cancer (mCRPC) patients treated with Radium-223 dichloride (Ra-223) over placebo. Here we report clinical outcomes of Ra-223 treatment in a nonstudy population. In this prospective registry, patients from 20 Dutch hospitals were included prior to Ra-223 treatment. Clinical parameters collected included previous treatments and Adverse Events. Primary outcome was 6 months Symptomatic Skeletal Event (SSE)-free survival, while secondary outcomes included Progression-Free Survival (PFS) and Overall Survival (OS). Of the 305 patients included, 300 were evaluable. The mean age was 73.6 years, 90% had ≥6 bone metastases and 74.1% were pretreated with Docetaxel, 19.5% with Cabazitaxe","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2025-04-29T10:52:16.699Z","creation":"2025-04-06T19:42:00.782Z"},"accession":"S-EPMC7383569","cross_references":{"pubmed":["31875956"],"doi":["10.1002/ijc.32851"]}}